Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 79.8% in October

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 9,100 shares, a decrease of 79.8% from the October 15th total of 45,100 shares. Based on an average daily trading volume, of 150,800 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Stock Performance

OTCMKTS:ALPMY traded up $0.04 on Tuesday, hitting $11.21. The company’s stock had a trading volume of 248,204 shares, compared to its average volume of 77,829. The firm has a market capitalization of $20.29 billion, a P/E ratio of 53.38 and a beta of 0.36. Astellas Pharma has a one year low of $9.15 and a one year high of $13.14. The company has a current ratio of 0.90, a quick ratio of 0.72 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average of $11.81 and a two-hundred day moving average of $10.94.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 EPS for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. The firm had revenue of $3.11 billion during the quarter. Research analysts predict that Astellas Pharma will post 0.56 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.